Non-invasive glucose Know Labs specializes in non-invasive blood glucose monitoring using Bio-RFID technology, presenting a clear opportunity to partner with manufacturers of diabetes management devices, wearables, and remote monitoring platforms seeking safer, painless glucose tracking solutions.

Public market entry As a publicly traded company (KNW NYSE American) with ongoing fundraising activity, there may be strategic opportunities to engage investors, OEM partners, and healthcare distributors looking to align with emerging medical diagnostics technologies and scalable manufacturing capabilities.

Early Gen device Generation 1 device launch signals near-term product availability; sales efforts can target device distributors, clinics, and wellness programs interested in piloting or integrating non-invasive glucose sensing into their portfolios.

Bio-RFID partnerships Existing collaborations with Edge Impulse and ongoing algorithm refinement initiatives indicate openness to co-development and data collaboration; this is a path to co-create value with AI/ML-focused healthtech integrators and CROs for clinical trials.

Global diabetes need With billions affected by diabetes and prediabetes, position Know Labs as a scalable diagnostic platform for real-time glucose data across wearables, mobile devices, and benchtop analyzers to expand into consumer and clinical markets through strategic OEM partnerships.